(Q35849204)

10 August 2017

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience (English)

1 reference

10 August 2017

chronic myeloid leukemia

0 references

1 reference

1 reference

1

Hagop Kantarjian

1 reference

10 August 2017

9

Stefan Faderl

1 reference

10 August 2017

15

Jorge Cortes

1 reference

10 August 2017

10

Tapan Kadia

1 reference

10 August 2017

2

Susan O'Brien

1 reference

10 August 2017

Alfonso Quintas-Cardama

series ordinal

5

object named as

Alfonso Quintas-Cardama

1 reference

10 August 2017

8

Farhad Ravandi

1 reference

10 August 2017

3

Elias Jabbour

1 reference

10 August 2017

11

Gautam Borthakur

1 reference

10 August 2017

7

Mary Beth Rios

1 reference

10 August 2017

13

Richard Champlin

1 reference

10 August 2017

12

Xuelin Huang

1 reference

10 August 2017

6

Jenny Shan

1 reference

10 August 2017

Guillermo Garcia-Manero

series ordinal

4

object named as

Guillermo Garcia-Manero

1 reference

10 August 2017

14

Moshe Talpaz

1 reference

10 August 2017

language of work or name

English

0 references

publication date

6 January 2012

1 reference

10 August 2017

1 reference

10 August 2017

119

1 reference

10 August 2017

9

1 reference

10 August 2017

1981-1987

1 reference

Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008

10 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3311242

Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3311242

Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3311242

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3311242

Therapy of lymphoid and undifferentiated chronic myelogenous leukemia in blast crisis with continuous vincristine and adriamycin infusions plus high-dose decadron

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3311242

Characteristics of accelerated disease in chronic myelogenous leukemia

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3311242

Recent trends in long-term survival of patients with chronic myelocytic leukemia: disclosing the impact of advances in therapy on the population level

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3311242

Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3311242

Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3311242

Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3311242

Prognostic discrimination in "good-risk" chronic granulocytic leukemia.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3311242

Survival advantage from imatinib compared with the combination interferon- plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3311242

Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia

14 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22228624

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1182/BLOOD-2011-08-358135

1 reference

10 August 2017

1 reference

10 August 2017

PubMed publication ID

22228624

1 reference